Carolina Urologic Research Center LLC

1. Pfizer Inc. $4,724,943 419 payments
2. Bayer HealthCare Pharmaceuticals Inc. $665,621 39 payments
3. Exelixis Inc. $513,864 48 payments
4. MacroGenics, Inc. $368,832 25 payments
5. Medivation Inc. $310,517 228 payments
6. Sumitomo Pharma America, Inc. $134,981 37 payments
7. Astellas Pharma Global Development $116,158 31 payments
8. Veru Inc. $94,717 12 payments
9. Merck Sharp & Dohme Corporation $53,878 6 payments
10. Ferring Pharmaceuticals AS $29,886 9 payments

1. A Phase 3 Multinational Randomized Openlabel Three Parallelarm Study of Pf06801591 An Antipd1 Antibody in Combination With Bacillus Calmetteguerin BCG Induction With Or Without BCG Maintenance Versus BCG Induction and Maintenance in Participants With Highrisk Bcgnaive Nonmuscle Invasive Bladder Cancer $2,024,966 87 payments
2. Talapro3 A Phase 3 Randomized Doubleblind Study of Talazoparib With Enzalutamide Versus Placebo With Enzalutamide in Men With DDR Gene Mutated Metastatic Castrationsensitive Prostate Cancer $1,035,708 78 payments
3. A Phase I Dose Escalation and Expanded Cohort Study of Pf06821497 in the Treatment of Adult Patients With Relapsedrefractory Small Cell Lung Cancer SCLC Castration Resistant Prostate Cancer CRPC and Follicular Lymphoma FL $693,126 52 payments
4. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $653,208 366 payments
5. BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical $398,931 8 payments
6. A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors $371,963 17 payments
7. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $203,423 11 payments
8. A Phase 3 Randomized Openlabel Study of Pf06821497 Mevrometostat in Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel in Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Mevpro1 $187,648 8 payments
9. BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer $143,950 4 payments
10. A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer $134,964 8 payments

1. Other $368,832 25 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.